Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)

Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)

Abstract Background Heterozygous familial hypercholesterolemia (HeFH) is largely underdiagnosed and undertreated in China where few patients achieved recommended target levels of low density lipoprotein cholesterol (LDL-C). We conducted the first randomized, placebo-controlled clinical trial in Chin...

Full description

Bibliographic Details
Main Authors: Meng Chai, Yongming He, Wang Zhao, Xuebin Han, Guoyan Zhao, Xueping Ma, Ping Qiao, Dongmei Shi, Yuyang Liu, Wei Han, Pei An, Haoyu Li, Shuling Yan, Qingyang Ma, Huan Deng, Lei Qian, Yujie Zhou, on behalf of CREDIT-2 investigators
Format: Article
Language:English
Published: BMC 2023-02-01
Series:BMC Medicine
Subjects:
Tafolecimab
PCSK9
LDL-C
HeFH
Online Access:https://doi.org/10.1186/s12916-023-02797-8

Internet

https://doi.org/10.1186/s12916-023-02797-8

Similar Items